Trevi Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Trevi Therapeutics, Inc. (TRVI) reported Earnings Per Share, Basic and Diluted of -$0.24 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-12
- Trevi Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.24.
- Trevi Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.34.
- Trevi Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.49.
- Trevi Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.43.
- Trevi Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$1.49.
- Trevi Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$1.81.
- Trevi Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2019 was -$2.28.
- Trevi Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2018 was -$58.44.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.24 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | -$1.49 10-K · filed 2022-03-17 | |||
| 2021-09-30 | -$0.34 10-Q · filed 2021-11-10 | -$1.25 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | -$0.49 10-Q · filed 2021-08-12 | -$0.92 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | -$0.43 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$0.52 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$0.92 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$1.34 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$1.81 10-K · filed 2022-03-17 |
| 2020-09-30 | -$0.41 10-Q · filed 2021-11-10 | -$0.82 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$1.30 10-Q · filed 2021-11-10 | -$1.66 derived: net income ÷ weighted average shares · filed 2021-11-10 |
| 2020-06-30 | -$0.41 10-Q · filed 2021-08-12 | -$0.89 10-Q · filed 2021-08-12 | -$1.25 derived: net income ÷ weighted average shares · filed 2021-08-12 | -$1.67 derived: net income ÷ weighted average shares · filed 2021-08-12 |
| 2020-03-31 | -$0.48 10-Q · filed 2021-05-13 | -$0.84 derived: net income ÷ weighted average shares · filed 2021-05-13 | -$1.25 derived: net income ÷ weighted average shares · filed 2021-05-13 | -$1.81 derived: net income ÷ weighted average shares · filed 2021-05-13 |
| 2019-12-31 | -$0.37 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$0.78 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$1.33 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$2.28 10-K · filed 2021-03-25 |
| 2019-09-30 | -$0.41 10-Q · filed 2020-11-12 | -$0.99 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$2.09 10-Q · filed 2020-11-12 | -$3.77 derived: net income ÷ weighted average shares · filed 2020-11-12 |
| 2019-06-30 | -$0.63 10-Q · filed 2020-08-13 | -$2.32 10-Q · filed 2020-08-13 | -$5.29 derived: net income ÷ weighted average shares · filed 2020-08-13 | -$9.19 derived: net income ÷ weighted average shares · filed 2020-08-13 |
| 2019-03-31 | -$13.85 10-Q · filed 2020-05-07 | -$30.60 derived: net income ÷ weighted average shares · filed 2020-05-07 | -$46.81 derived: net income ÷ weighted average shares · filed 2020-05-07 | -$60.44 derived: net income ÷ weighted average shares · filed 2020-05-07 |
| 2018-12-31 | -$16.76 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$32.98 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$46.60 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$58.44 10-K · filed 2020-03-16 |
| 2018-09-30 | -$16.22 10-Q · filed 2019-11-14 | -$29.84 derived: net income ÷ weighted average shares · filed 2019-11-14 | -$41.68 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$13.62 10-Q · filed 2019-08-12 | -$25.45 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$11.82 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |